TABLE 1.

Selectivity of CPL500036 (1 μM). This table presents percent inhibition of specific binding of the control. “Interaction” is denoted by control specific binding > 25%.

Protein	% Inh	Protein	% Inh
adenosine A2A receptor (h)*	−8.1	µ -type opioid receptor (h)*	−1.1
alpha-1A adrenergic receptor (h)	1.8	serotonin receptor 1A (h)*	5.4
alpha-2A adrenergic receptor (h)	0.4	serotonin receptor 1B (r)	−7.3
beta-1 adrenergic receptor (h)*	1.1	serotonin receptor 2A (h)*	−8.6
beta-2 adrenergic receptor (h)*	8.2	serotonin receptor 2B (h)*	10.6
benzodiazepine receptor (GABAA) (r)*	−27.7	serotonin receptor 3 (h)	−5.7
cannabinoid receptor type 1 (h)*	8.8	glucocorticoid receptor (h)*	−3.2
cannabinoid receptor type 2 (h)*	−14.6	androgen receptor (h)*	5.3
cholecystokinin A receptor (h)*	−8.2	vasopressin receptor (h)*	−0.8
dopamine receptor type 1 (h)	−8.2	calcium channel, voltage-dependent, L type (r)	−7.2
dopamine receptor type 2 (h)*	−14.4	potassium voltage-gated channel subfamily H member 2 (h)	−19.6
Endothelin receptor (h)*	−16.8	α-dendrotoxin sensitive potassium channel (r)	−10.2
N-Methyl-d-aspartic acid receptor (r)	4.4	voltage-gated sodium channels site 2 (r)	−1.3
histamine receptor type 1 (h)	−14.6	norepinephrine transporter (h)	−14.5
histamine receptor type 2 (h)	1.8	dopamine transporter (h)	−6.9
Monoamine oxidase A (r)	1.0	5-HT transporter (h)	-9.5
muscarinic acetylcholine receptor type 1 (h)	−19.7	Cyclooxygenase 1 (h)	−9.5
muscarinic acetylcholine receptor type 2 (h)	−91.2	Cyclooxygenase 2 (h)	−0.4
muscarinic acetylcholine receptor type 3 (h)	0.7	phosphodiesterase 3A (h)	−15.2
alpha 4/beta 2 nicotinic acetylcholine receptor, (neuronal) (h)*	−6.1	phosphodiesterase 4 (h)	0.8
δ-type opioid receptor ẟ2 (h)*	6.9	lymphocyte-specific protein tyrosine kinase (h)	−1.9
κ-type opioid receptor (r)*	7.7	Acetylcholinesterase (h)	13.7

Abbreviations: h–human, r–rat, % inh. - % inhibition of control specific binding, * - agonist radioligand.